Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDSupernus Pharmaceuticals Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | $0.29 | $0.30 | $0.30 |
| Q2 2026 | 2 | $0.43 | $0.55 | $0.49 |
| Q3 2026 | 1 | $0.64 | $0.66 | $0.65 |
| Q4 2026 | 1 | $0.71 | $0.74 | $0.73 |
| Q1 2027 | 1 | $0.46 | $0.48 | $0.47 |
| Q2 2027 | 1 | $0.68 | $0.71 | $0.69 |
| Q3 2027 | 1 | $0.90 | $0.94 | $0.92 |
| Q4 2027 | 1 | $1.01 | $1.06 | $1.04 |
Supernus Pharmaceuticals Inc Earnings Date And Information
Supernus Pharmaceuticals Inc last posted its earnings results on Tuesday, May 5th, 2026. The company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.31. The company had revenue of 207.71 M for the quarter and had revenue of 718.95 M for the year. Supernus Pharmaceuticals Inc has generated $-1 earnings per share over the last year ($-0.68 diluted earnings per share) and currently has a price-to-earnings ratio of -104.01. Supernus Pharmaceuticals Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Supernus Pharmaceuticals Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/05/2026 | Q1 2026 | $0.28 | -$0.04 | -0.32 | $192.92 M | $207.71 M |
| 03/02/2026 | Q4 2025 | N/A | -$0.07 | N/A | $195.16 M | $211.57 M |
| 11/06/2025 | Q3 2025 | N/A | -$0.80 | N/A | $180.22 M | $192.10 M |
| 08/05/2025 | Q2 2025 | $0.47 | $0.40 | -0.07 | $154.06 M | $165.45 M |
| 05/06/2025 | Q1 2025 | $0.38 | -$0.21 | -0.59 | $147.94 M | $149.82 M |
| 02/25/2025 | Q4 2024 | $0.46 | $0.28 | -0.18 | $155.25 M | $174.16 M |
| 11/04/2024 | Q3 2024 | $0.39 | $0.70 | 0.31 | $157.35 M | $175.69 M |
| 08/06/2024 | Q2 2024 | $0.31 | $0.36 | 0.05 | $148.83 M | $168.33 M |
| 05/08/2024 | Q1 2024 | $0.38 | $0.00 | -0.38 | $145.83 M | $143.64 M |
| 02/27/2024 | Q4 2023 | $0.41 | $0.02 | -0.39 | N/A | $164.31 M |
| 11/08/2023 | Q3 2023 | $0.13 | -$0.29 | -0.42 | N/A | $153.88 M |
| 08/08/2023 | Q2 2023 | $0.23 | -$0.02 | -0.25 | N/A | $135.56 M |
| 05/09/2023 | Q1 2023 | $0.17 | $0.31 | 0.14 | N/A | $153.76 M |
| 03/09/2023 | Q4 2022 | N/A | $0.47 | N/A | N/A | $167.33 M |
| 11/09/2022 | Q3 2022 | N/A | $0.03 | N/A | N/A | $177.35 M |
| 08/08/2022 | Q2 2022 | N/A | $0.15 | N/A | N/A | $170.05 M |
| 05/12/2022 | Q1 2022 | N/A | $0.48 | N/A | N/A | $152.51 M |
| 04/13/2022 | Q4 2021 | $0.24 | $0.05 | -0.19 | N/A | $159.05 M |
| 11/05/2021 | Q3 2021 | N/A | $0.41 | N/A | N/A | $148.46 M |
| 08/06/2021 | Q2 2021 | N/A | $0.45 | N/A | N/A | $141.33 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Supernus Pharmaceuticals Inc Earnings: FAQ's
In the previous quarter, Supernus Pharmaceuticals Inc (:SUPN) reported $0.59 earnings per share (EPS) to beat the analysts' consensus estimate of $0.28 by $0.31.
The conference call for Supernus Pharmaceuticals Inc's latest earnings report can be listened to online.
The conference call transcript for Supernus Pharmaceuticals Inc's latest earnings report can be read online.
Supernus Pharmaceuticals Inc (:SUPN) has a recorded annual revenue of $718.95 M.
Supernus Pharmaceuticals Inc (:SUPN) has a recorded net income of $-38,550,000.Supernus Pharmaceuticals Inc has generated $-0.68 earnings per share over the last four quarters.
Supernus Pharmaceuticals Inc (:SUPN) has a price-to-earnings ratio of -104.01 and price/earnings-to-growth ratio is 1.06.